Temperature-controlled continous wave (cw)-laser treatment for CSR patients (TempLaser)

Temperature-controlled continous wave (cw)-laser treatment for CSR patients (TempLaser) - TempLaser

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00028581

Enrollment

Registered

2022-03-22

Start date

2022-03-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H35.7

Interventions

Group 1: Patients with chronic retinopathy centralis serosa are treated with a CE-certified cw laser. One laser treatment (approx. 10-15min) was carried out in this study. A new module is coupled betw

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - of legal age - central serous retinopathy for more than 3 months - Leackage point at least 500µm outside the fovea

Exclusion criteria

Exclusion criteria: - underage - Initial RCS diagnosis less than 3 months - Leackage point <500µm away from the fovea

Design outcomes

Primary

Measure	Time frame
Therapy safety controlled by: - Microperimetry - mERG - Optical coherence tomography - Fluorescence angiography - Fundus photography	—

Secondary

Measure	Time frame
Therapy success controlled by: - Optical coherence tomography - Subjective improvement (analogue scale)	—

Countries

Germany

Contacts

Public ContactClaus von der Burchard

Klinik für Ophthalmologie Universitätsklinikum Schleswig-Holstein Campus Kiel

claus.vonderburchard@uksh.de0431 500 24202

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026